Myra Vision is developing a treatment intended to allow maximum intraocular pressure (IOP) reduction for patients with moderate to advanced glaucoma. The company is developing the Calibreye System, a novel treatment designed to allow safe outflow control to achieve maximum IOP reduction while reducing complexity and complication rates. Myra Vision is led by President and CEO Robert Chang. The company intends to use new funding to further product development, scale manufacturing capabilities, and support first-in-human investigation of the Calibreye System. It is a privately held portfolio company of Shifamed. The firm completed a $25M Series B to support these activities. Myra Vision is developing a glaucoma treatment device built around novel technology designed to allow safe outflow control to achieve maximum intraocular pressure (IOP) reduction while reducing complexity and complication rates. The company is based in Campbell, Calif., and is a Shifamed portfolio company. Led by CEO Robert Chang, Myra Vision intends to use its recent financing to advance product development, scale infrastructure, and expand its team. The company completed a $17M Series A financing and announced a name change to Myra Vision, Inc. from Myra Medical, Inc. The funding is intended to support continued development and commercialization efforts for its glaucoma treatment device. Myra Medical is a newly formed Shifamed portfolio company advancing surgical devices designed to enable maximum intraocular pressure (IOP) reduction. Its novel technology aims to safely reduce IOP while lowering the risk of hypotony, targeting improved treatment for moderate to advanced glaucoma patients. The company intends to use its recent funding to advance product development and pre-clinical programs. Myra Medical has appointed Robert Chang as Chief Executive Officer and Tracy Valorie as a strategic advisor; both bring extensive ophthalmology and medical-device experience. The company raised seed financing in 2019 to support these development plans. Shifamed, founded by serial entrepreneur Amr Salahieh, serves as the medical innovation hub backing the company.

Total raised

$45M

Funding rounds

3

Latest round

Series B

Latest activity

Jun 2023